Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Radioiodine in RAI-Refractory Thyroid Cancers
NCT02152995Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2014
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib in thyroid carcinoma (TC) (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Percentage of Patients Progression Free at 6 months, Progression Free Survival at 6 months and 2 more. Started Aug 2014; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT02152995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152995.